

Applicants: Samuel C. Silverstein, et al.
Serial No: 09/658,698
Filed: September 8, 2000
Page 2

- A. a method comprising the use of a type O red blood cell ghost as recited in claims 2 and 18, or a liposome as recited in claims 3 and 19;
- B. a method comprising the use of a specific ligand, such as one of the ligands recited in claims 4 and 20;
- C. a method comprising the use of a specific antigen presenting cell as recited in claims 5 and 17;
- D. a method comprising the use of a specific antigen such as one recited in claims 10 and 22;
- E. a method comprising the use of a specific stimulatory cytokine such as one recited in claims 12 and 28;
- F. a method wherein the immunity induced is against a specific antigen or a specific cancerous tumor as recited in claims 13,14, 29 and 30;
- G. a method relating to a specific disease such as one recited in claims 15, 16, 31 and 32; and
- H. a method wherein an antigen is administered in a specific manner, such as directly to the subject as embodied in claim 1, or ex vivo, as embodied by claim 17.

In response, applicants hereby elect with traverse the following species corresponding to the Examiner's above listed categories:

Applicants: Samuel C. Silverstein, et al.
Serial No: 09/658,698
Filed: September 8, 2000
Page 3

- A. a method comprising the use of a type O red blood cell ghost (upon which claims 1, 2, 17 and 18 read);
- B. a method comprising the use of an immunoglobulin (upon which claims 1, 4, 17, and 20 read);
- C. a method comprising the use of a mononuclear phagocyte (upon which claims 1, 5, 17 and 21 read);
- D. a method comprising the use of a peptide (upon which claims 1, 10, 17 and 26 read);
- E. a method comprising the use of GM-CSF (upon which claims 1, 12, 17 and 28 read);
- F. a method wherein the immunity induced is against a cancerous tumor (upon which claims 1, 14, 17 and 30 read);
- G. a method relating to cancer (upon which claims 1, 16, 17 and 32 read); and
- H. a method wherein an antigen is administered directly to the subject (upon which claim 1 reads).

REMARKS

Claims 1-32 are pending in the subject application. The Examiner has required applicants to elect one species from each of eight categories, and set forth the claims upon which each elected